Jonathan Block

Jason Bednar

Joseph Federico

Xuesong Wang

- SonoThera™ will present new data at the 32nd congress of the European Society of Gene and Cell Therapy (ESGCT) on **Thursday, October 9, 2025**, focusing on its proprietary ultrasound-mediated delivery (UMD) technology for treating Duchenne Muscular Dystrophy (DMD).  **[1407973_afbfa0632b57437ab6bb9c2159545b2b_0]** 
- The data demonstrates the UMD technology's ability to deliver genetic medicines, enabling **full-length human dystrophin protein expression** in skeletal, heart, and diaphragm muscle tissue in murine and non-human primate (NHP) models.  **[1407973_afbfa0632b57437ab6bb9c2159545b2b_0]** 
- Results show **high levels of durable human dystrophin protein expression exceeding 50% of endogenous levels** have been achieved in NHP.  **[1407973_afbfa0632b57437ab6bb9c2159545b2b_0]** 
- SonoThera's RIPPLE™ UMD approach is a **nonviral, non-invasive, and redosable method** designed to overcome current gene therapy delivery limitations, allowing for broad, highly targeted biodistribution of diverse genetic payloads without size restriction.  **[1407973_afbfa0632b57437ab6bb9c2159545b2b_0]**

Sonendo (SONX)